# EDGAR Filing Document

**Accession Number:** 0001131399
**File Stem:** 0001654954-26-005880
**Filing Date:** 2026-6
**Character Count:** 34808
**Document Hash:** e88d31f2314719ffbb91211e4cc55624
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001654954-26-005880.hdr.sgml**: 20260611

**ACCESSION NUMBER**: 0001654954-26-005880

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260611

**FILED AS OF DATE**: 20260611

**DATE AS OF CHANGE**: 20260611

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** GSK plc
- **CENTRAL INDEX KEY:** 0001131399
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** X0

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-15170
- **FILM NUMBER:** 261081786

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 79 NEW OXFORD STREET
- **CITY:** LONDON
- **PROVINCE COUNTRY:** X0
- **ZIP:** WC1A 1DG
- **BUSINESS PHONE:** 44 20 8047 5000

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 79 NEW OXFORD STREET
- **CITY:** LONDON
- **PROVINCE COUNTRY:** X0
- **ZIP:** WC1A 1DG

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GSK PLC
- **DATE OF NAME CHANGE:** 20220516

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GLAXOSMITHKLINE PLC
- **DATE OF NAME CHANGE:** 20010105

**UNITED STATES**

 **SECURITIES AND EXCHANGE COMMISSION**

 **Washington, D.C. 20549**

 **Form 6-K**

 **REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16**

 **UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of June 2026

Commission File Number 001-15170

 **GSK plc**

(Translation of registrant's name into English)

 **79 New Oxford Street, London, WC1A 1DG**

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

 **GSK plc (the 'Company')**

Transaction notification

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; **1.**<br>| &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** | &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** | &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; a)<br>| &nbsp;&nbsp;&nbsp; Name | Lynn Baxter | Lynn Baxter |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; b)<br>| &nbsp;&nbsp;&nbsp; Position/status | President, Europe | President, Europe |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; c)<br>| &nbsp;&nbsp;&nbsp; Initial notification/amendment | Initial notification | Initial notification |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; **2.**<br>| &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; a)<br>| &nbsp;&nbsp;&nbsp; Name | GSK plc | GSK plc |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; b)<br>| &nbsp;&nbsp;&nbsp; LEI | 5493000HZTVUYLO1D793 | 5493000HZTVUYLO1D793 |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; **3.**<br>| &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | &nbsp;&nbsp;&nbsp; Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br> ISIN: GB00BN7SWP63 | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br> ISIN: GB00BN7SWP63 |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; b)<br>| &nbsp;&nbsp;&nbsp; Nature of the transaction | Acquisition of Ordinary Shares under the Company's Share Reward Plan | Acquisition of Ordinary Shares under the Company's Share Reward Plan |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) | Price(s) | Volume(s) |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) | £18.8393 | 7 (partnership shares) |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) | £18.8393 | 7 (matching shares) |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | &nbsp;&nbsp;&nbsp; Aggregated information<br>|  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | &nbsp;&nbsp;&nbsp; Aggregated volume Price | 14 Ordinary Shares<br> £18.8393 | 14 Ordinary Shares<br> £18.8393 |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; e)<br>| &nbsp;&nbsp;&nbsp; Date of the transaction | 2026-06-09 | 2026-06-09 |
| &nbsp;&nbsp;&nbsp;&nbsp; f) | &nbsp;&nbsp;&nbsp; Place of the transaction<br>| London Stock Exchange (XLON) | London Stock Exchange (XLON) |

---

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; **1.**<br>| &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** | &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** | &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; a)<br>| &nbsp;&nbsp;&nbsp; Name | Julie Brown | Julie Brown |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; b)<br>| &nbsp;&nbsp;&nbsp; Position/status | Chief Financial Officer | Chief Financial Officer |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Initial notification/amendment<br>| Initial notification | Initial notification |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; **2.**<br>| &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; a)<br>| &nbsp;&nbsp;&nbsp; Name | GSK plc | GSK plc |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; b)<br>| &nbsp;&nbsp;&nbsp; LEI | 5493000HZTVUYLO1D793 | 5493000HZTVUYLO1D793 |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; **3.**<br>| &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | &nbsp;&nbsp;&nbsp; Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br> ISIN: GB00BN7SWP63 | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br> ISIN: GB00BN7SWP63 |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; b)<br>| &nbsp;&nbsp;&nbsp; Nature of the transaction | Acquisition of Ordinary Shares under the Company's Share Reward Plan | Acquisition of Ordinary Shares under the Company's Share Reward Plan |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) | Price(s) | Volume(s) |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) | £18.8393 | 7 (partnership shares) |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) | £18.8393 | 7 (matching shares) |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | &nbsp;&nbsp;&nbsp; Aggregated information<br>|  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | &nbsp;&nbsp;&nbsp; Aggregated volume Price | 14 Ordinary Shares<br> £18.8393 | 14 Ordinary Shares<br> £18.8393 |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; e)<br>| &nbsp;&nbsp;&nbsp; Date of the transaction | 2026-06-09 | 2026-06-09 |
| &nbsp;&nbsp;&nbsp;&nbsp; f) | &nbsp;&nbsp;&nbsp; Place of the transaction<br>| London Stock Exchange (XLON) | London Stock Exchange (XLON) |

---

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; **1.**<br>| &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** | &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** | &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; a)<br>| &nbsp;&nbsp;&nbsp; Name | James Ford | James Ford |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; b)<br>| &nbsp;&nbsp;&nbsp; Position/status | SVP and Group General Counsel, Legal and Compliance | SVP and Group General Counsel, Legal and Compliance |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Initial notification/amendment<br>| Initial notification | Initial notification |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; **2.**<br>| &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; a)<br>| &nbsp;&nbsp;&nbsp; Name | GSK plc | GSK plc |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; b)<br>| &nbsp;&nbsp;&nbsp; LEI | 5493000HZTVUYLO1D793 | 5493000HZTVUYLO1D793 |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; **3.**<br>| &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | &nbsp;&nbsp;&nbsp; Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br> ISIN: GB00BN7SWP63 | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br> ISIN: GB00BN7SWP63 |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; b)<br>| &nbsp;&nbsp;&nbsp; Nature of the transaction | Acquisition of Ordinary Shares under the Company's Share Reward Plan | Acquisition of Ordinary Shares under the Company's Share Reward Plan |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) | Price(s) | Volume(s) |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) | £18.8393 | 7 (partnership shares) |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) | £18.8393 | 7 (matching shares) |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | &nbsp;&nbsp;&nbsp; Aggregated information<br>|  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | &nbsp;&nbsp;&nbsp; Aggregated volume Price | 14 Ordinary Shares<br> £18.8393 | 14 Ordinary Shares<br> £18.8393 |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; e)<br>| &nbsp;&nbsp;&nbsp; Date of the transaction | 2026-06-09 | 2026-06-09 |
| &nbsp;&nbsp;&nbsp;&nbsp; f) | &nbsp;&nbsp;&nbsp; Place of the transaction<br>| London Stock Exchange (XLON) | London Stock Exchange (XLON) |

---

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; **1.**<br>| &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** | &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** | &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; a)<br>| &nbsp;&nbsp;&nbsp; Name | David Redfern | David Redfern |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; b)<br>| &nbsp;&nbsp;&nbsp; Position/status | President, Corporate Development | President, Corporate Development |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Initial notification/amendment<br>| Initial notification | Initial notification |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; **2.**<br>| &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; a)<br>| &nbsp;&nbsp;&nbsp; Name | GSK plc | GSK plc |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; b)<br>| &nbsp;&nbsp;&nbsp; LEI | 5493000HZTVUYLO1D793 | 5493000HZTVUYLO1D793 |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; **3.**<br>| &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | &nbsp;&nbsp;&nbsp; Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br> ISIN: GB00BN7SWP63 | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br> ISIN: GB00BN7SWP63 |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; b)<br>| &nbsp;&nbsp;&nbsp; Nature of the transaction | Acquisition of Ordinary Shares under the Company's Share Reward Plan | Acquisition of Ordinary Shares under the Company's Share Reward Plan |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) | Price(s) | Volume(s) |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) | £18.8393 | 7 (partnership shares) |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) | £18.8393 | 7 (matching shares) |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | &nbsp;&nbsp;&nbsp; Aggregated information<br>|  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | &nbsp;&nbsp;&nbsp; Aggregated volume Price | 14 Ordinary Shares<br> £18.8393 | 14 Ordinary Shares<br> £18.8393 |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; e)<br>| &nbsp;&nbsp;&nbsp; Date of the transaction | 2026-06-09 | 2026-06-09 |
| &nbsp;&nbsp;&nbsp;&nbsp; f) | &nbsp;&nbsp;&nbsp; Place of the transaction<br>| London Stock Exchange (XLON) | London Stock Exchange (XLON) |

---

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; **1.**<br>| &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** | &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** | &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; a)<br>| &nbsp;&nbsp;&nbsp; Name | Regis Simard | Regis Simard |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; b)<br>| &nbsp;&nbsp;&nbsp; Position/status | President, Global Supply Chain | President, Global Supply Chain |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Initial notification/amendment<br>| Initial notification | Initial notification |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; **2.**<br>| &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; a)<br>| &nbsp;&nbsp;&nbsp; Name | GSK plc | GSK plc |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; b)<br>| &nbsp;&nbsp;&nbsp; LEI | 5493000HZTVUYLO1D793 | 5493000HZTVUYLO1D793 |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; **3.**<br>| &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | &nbsp;&nbsp;&nbsp; Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br> ISIN: GB00BN7SWP63 | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br> ISIN: GB00BN7SWP63 |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; b)<br>| &nbsp;&nbsp;&nbsp; Nature of the transaction | Acquisition of Ordinary Shares under the Company's Share Reward Plan | Acquisition of Ordinary Shares under the Company's Share Reward Plan |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) | Price(s) | Volume(s) |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) | £18.8393 | 7 (partnership shares) |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) | £18.8393 | 7 (matching shares) |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | &nbsp;&nbsp;&nbsp; Aggregated information<br>|  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | &nbsp;&nbsp;&nbsp; Aggregated volume Price | 14 Ordinary Shares<br> £18.8393 | 14 Ordinary Shares<br> £18.8393 |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; e)<br>| &nbsp;&nbsp;&nbsp; Date of the transaction | 2026-06-09 | 2026-06-09 |
| &nbsp;&nbsp;&nbsp;&nbsp; f) | &nbsp;&nbsp;&nbsp; Place of the transaction<br>| London Stock Exchange (XLON) | London Stock Exchange (XLON) |

---

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; **1.**<br>| &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** | &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** | &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; a)<br>| &nbsp;&nbsp;&nbsp; Name | Philip Thomson | Philip Thomson |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; b)<br>| &nbsp;&nbsp;&nbsp; Position/status | President, Global Affairs | President, Global Affairs |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Initial notification/amendment<br>| Initial notification | Initial notification |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; **2.**<br>| &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; a)<br>| &nbsp;&nbsp;&nbsp; Name | GSK plc | GSK plc |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; b)<br>| &nbsp;&nbsp;&nbsp; LEI | 5493000HZTVUYLO1D793 | 5493000HZTVUYLO1D793 |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; **3.**<br>| &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | &nbsp;&nbsp;&nbsp; Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br> ISIN: GB00BN7SWP63 | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br> ISIN: GB00BN7SWP63 |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; b)<br>| &nbsp;&nbsp;&nbsp; Nature of the transaction | Acquisition of Ordinary Shares under the Company's Share Reward Plan | Acquisition of Ordinary Shares under the Company's Share Reward Plan |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) | Price(s) | Volume(s) |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) | £18.8393 | 7 (partnership shares) |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) | £18.8393 | 7 (matching shares) |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | &nbsp;&nbsp;&nbsp; Aggregated information<br>|  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | &nbsp;&nbsp;&nbsp; Aggregated volume Price | 14 Ordinary Shares<br> £18.8393 | 14 Ordinary Shares<br> £18.8393 |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; e)<br>| &nbsp;&nbsp;&nbsp; Date of the transaction | 2026-06-09 | 2026-06-09 |
| &nbsp;&nbsp;&nbsp;&nbsp; f) | &nbsp;&nbsp;&nbsp; Place of the transaction<br>| London Stock Exchange (XLON) | London Stock Exchange (XLON) |

---

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; **1.**<br>| &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** | &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** | &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; a)<br>| &nbsp;&nbsp;&nbsp; Name | Deborah Waterhouse | Deborah Waterhouse |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; b)<br>| &nbsp;&nbsp;&nbsp; Position/status | CEO, ViiV Healthcare and President, Global Health, GSK | CEO, ViiV Healthcare and President, Global Health, GSK |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Initial notification/amendment<br>| Initial notification | Initial notification |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; **2.**<br>| &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; a)<br>| &nbsp;&nbsp;&nbsp; Name | GSK plc | GSK plc |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; b)<br>| &nbsp;&nbsp;&nbsp; LEI | 5493000HZTVUYLO1D793 | 5493000HZTVUYLO1D793 |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; **3.**<br>| &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | &nbsp;&nbsp;&nbsp; Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br> ISIN: GB00BN7SWP63 | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br> ISIN: GB00BN7SWP63 |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; b)<br>| &nbsp;&nbsp;&nbsp; Nature of the transaction | Acquisition of Ordinary Shares under the Company's Share Reward Plan | Acquisition of Ordinary Shares under the Company's Share Reward Plan |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) | Price(s) | Volume(s) |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) | £18.8393 | 7 (partnership shares) |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) | £18.8393 | 7 (matching shares) |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | &nbsp;&nbsp;&nbsp; Aggregated information<br>|  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | &nbsp;&nbsp;&nbsp; Aggregated volume Price | 14 Ordinary Shares<br> £18.8393 | 14 Ordinary Shares<br> £18.8393 |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; e)<br>| &nbsp;&nbsp;&nbsp; Date of the transaction | 2026-06-09 | 2026-06-09 |
| &nbsp;&nbsp;&nbsp;&nbsp; f) | &nbsp;&nbsp;&nbsp; Place of the transaction<br>| London Stock Exchange (XLON) | London Stock Exchange (XLON) |

---

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; **1.**<br>| &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** | &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** | &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; a)<br>| &nbsp;&nbsp;&nbsp; Name | Victoria Whyte | Victoria Whyte |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; b)<br>| &nbsp;&nbsp;&nbsp; Position/status | SVP & Company Secretary | SVP & Company Secretary |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Initial notification/amendment<br>| Initial notification | Initial notification |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; **2.**<br>| &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; a)<br>| &nbsp;&nbsp;&nbsp; Name | GSK plc | GSK plc |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; b)<br>| &nbsp;&nbsp;&nbsp; LEI | 5493000HZTVUYLO1D793 | 5493000HZTVUYLO1D793 |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; **3.**<br>| &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | &nbsp;&nbsp;&nbsp; Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br> ISIN: GB00BN7SWP63 | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br> ISIN: GB00BN7SWP63 |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; b)<br>| &nbsp;&nbsp;&nbsp; Nature of the transaction | Acquisition of Ordinary Shares under the Company's Share Reward Plan | Acquisition of Ordinary Shares under the Company's Share Reward Plan |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) | Price(s) | Volume(s) |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) | £18.8393 | 6 (partnership shares) |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) | £18.8393 | 6 (matching shares) |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | &nbsp;&nbsp;&nbsp; Aggregated information<br>|  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | &nbsp;&nbsp;&nbsp; Aggregated volume Price | 12 Ordinary Shares<br> £18.8393 | 12 Ordinary Shares<br> £18.8393 |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; e)<br>| &nbsp;&nbsp;&nbsp; Date of the transaction | 2026-06-09 | 2026-06-09 |
| &nbsp;&nbsp;&nbsp;&nbsp; f) | &nbsp;&nbsp;&nbsp; Place of the transaction<br>| London Stock Exchange (XLON) | London Stock Exchange (XLON) |

---

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; **1.**<br>| &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** | &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** | &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; a)<br>| &nbsp;&nbsp;&nbsp; Name | Neil Falkingham | Neil Falkingham |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; b)<br>| &nbsp;&nbsp;&nbsp; Position/status | PCA of Lynn Baxter (President, Europe) | PCA of Lynn Baxter (President, Europe) |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Initial notification/amendment<br>| Initial notification | Initial notification |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; **2.**<br>| &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; a)<br>| &nbsp;&nbsp;&nbsp; Name | GSK plc | GSK plc |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; b)<br>| &nbsp;&nbsp;&nbsp; LEI | 5493000HZTVUYLO1D793 | 5493000HZTVUYLO1D793 |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; **3.**<br>| &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | &nbsp;&nbsp;&nbsp; Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br> ISIN: GB00BN7SWP63 | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br> ISIN: GB00BN7SWP63 |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; b)<br>| &nbsp;&nbsp;&nbsp; Nature of the transaction | Acquisition of Ordinary Shares under the Company's Share Reward Plan | Acquisition of Ordinary Shares under the Company's Share Reward Plan |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) | Price(s) | Volume(s) |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) | £18.8393 | 6 (partnership shares) |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) | £18.8393 | 6 (matching shares) |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | &nbsp;&nbsp;&nbsp; Aggregated information<br>|  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | &nbsp;&nbsp;&nbsp; Aggregated volume Price | 12 Ordinary Shares<br> £18.8393 | 12 Ordinary Shares<br> £18.8393 |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; e)<br>| &nbsp;&nbsp;&nbsp; Date of the transaction | 2026-06-09 | 2026-06-09 |
| &nbsp;&nbsp;&nbsp;&nbsp; f) | &nbsp;&nbsp;&nbsp; Place of the transaction<br>| London Stock Exchange (XLON) | London Stock Exchange (XLON) |

---

 **About GSK**

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at <u>www.gsk.com</u>.

 **Registered in England & Wales:**

No. 3888792

 **Registered Office:**

79 New Oxford Street

London

WC1A 1DG

 **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

---

| | |
|:---|:---|
|  | **GSK plc** |
|  | (Registrant) |
| Date: June 11, 2026 |  |
|  | By:/s/ VICTORIA WHYTE<br> -------------------------- |
|  | Victoria Whyte |
|  | Authorised Signatory for and on |
|  | behalf of GSK plc |

---

<br>